RA
NBIX icon

Riversedge Advisors’s Neurocrine Biosciences NBIX Stock Holding History

Riversedge Advisors’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$291K Buy
1,726
+175
+11% +$26K 0.04% 213
2026
Q1 		$204K Buy
+1,551
New +$206K 0.03% 206

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Riversedge Advisors's NBIX Position: Q2 2026 in Review

Riversedge Advisors increased its Neurocrine Biosciences (NBIX) stake by 11% in Q2 2026, buying an estimated $26K and bringing the position to 1,726 shares worth $291K. The position accounts for 0.04% of the portfolio, ranked #213.

Riversedge Advisors first reported a position in NBIX in Q1 2026 and has held it in 2 quarters since. 772 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Riversedge Advisors held 1,726 shares of Neurocrine Biosciences worth $291K as of Q2 2026.
  • Riversedge Advisors bought 175 Neurocrine Biosciences shares in Q2 2026, an estimated $26K.
  • Neurocrine Biosciences made up 0.04% of Riversedge Advisors's portfolio in Q2 2026, its #213 holding.
  • Riversedge Advisors first reported a position in Neurocrine Biosciences in Q1 2026 and has held it in 2 quarters since.
  • 772 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Riversedge Advisors's 13F filing for Q2 2026, filed 16 Jul 2026.